Quizartinib drug introduction and research and development background

Quizartinib (Quizartinib) is a new type of FLT3 inhibitor that specifically targets the common FLT3 gene mutation in acute myeloid leukemia (AML) . FLT3 is a cell surface receptor, and its mutations (such as FLT3 internal tandem duplications, ITD) are closely related to the occurrence and progression of AML. The mechanism of action of Quizartinib is to prevent the proliferation and survival of cancer cells by inhibiting the kinase activity of the FLT3 receptor, thereby achieving therapeutic effects.

1. R&D background

Quizatinib was developed byDAIICHI SANKYO, INC. Its main goal is to provide an effective targeted therapy for patients with FLT3 mutation-positive AML. FLT3 mutation positivity is a high-risk factor in AML, leading to poor disease prognosis. Therefore, the development of targeted drugs targeting FLT3 has become a new direction in the treatment of AML.

Quizatinib has shown strong inhibitory effects on FLT3 in preclinical experiments, and can effectively inhibit the proliferation of cancer cells caused by FLT3 mutations. Early clinical trial results also show that quizartinib shows better efficacy in the treatment of AML, and has a lower relapse rate and a higher complete remission rate compared with traditional chemotherapy.

2. Clinical development process

Quizatinib’s clinical research mainly focuses on the treatment of patients with FLT3 mutation-positive AML. After multiple phases of clinical trials, quizartinib has been proven to be used in combination with standard chemotherapy drugs to significantly improve the treatment effect of patients, especially during the maintenance treatment phase, and can effectively extend the disease-free survival of patients.

In summary, quizartinib has shown good clinical efficacy in the treatment of FLT3 mutation-positive acute myeloid leukemia.尽管其疗效突出，但治疗过程中需要综合考虑患者的具体情况和副作用管理。 With the accumulation of clinical data, the application of quizartinib has gradually expanded, becoming one of the important treatment options for patients with FLT3 mutation-positive AML.

Keyword tags: Quizartinib, drug introduction, research and development background,FLT3, acute myeloid leukemia

References：https://www.medicines.org.uk/emc/product/15557/smpc